Last reviewed · How we verify
Cotadutide 600 micrograms
Cotadutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels.
Cotadutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels. Used for Treatment of type 2 diabetes.
At a glance
| Generic name | Cotadutide 600 micrograms |
|---|---|
| Also known as | MEDI0382 |
| Sponsor | AstraZeneca |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By activating the GLP-1 receptor, cotadutide increases insulin secretion, decreases glucagon levels, and slows gastric emptying, leading to improved glycemic control. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cotadutide 600 micrograms CI brief — competitive landscape report
- Cotadutide 600 micrograms updates RSS · CI watch RSS
- AstraZeneca portfolio CI